Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCYOPR)

Drug Name

Anti-CD-20 mab Drug Info

Synonyms

Anti-CD-20 mAb (undisclosed indication); Anti-CD-20 mAb (undisclosed indication), PharmAbcine; CD-20 inhibitor (mAb, undisclosed indication), PharmAbcine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

TTD Drug ID: DMCYOPR

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Leukocyte surface antigen Leu-16 (CD20)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[3]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[4]
Ibritumomab	DMG594T	Non-hodgkin lymphoma	2B33.5	Approved	[5]
Rituximab	DM1YVZT	Central nervous system non-hodgkin lymphoma		Approved	[6]
Ublituximab	DMHTY9W	Multiple sclerosis	8A40	Approved	[7]
Tositumomab	DMMYZ3D	Non-hodgkin lymphoma	2B33.5	Approved	[5]
Obinutuzumab	DM3BVAE	Chronic lymphocytic leukaemia	2A82.0	Approved	[1]
Ofatumumab	DM295PR	Chronic lymphocytic leukaemia	2A82.0	Approved	[8]
Rituximab	DM1YVZT	Central nervous system non-hodgkin lymphoma		Approved	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
4	Clinical pipeline report, company report or official report of Genmab.
5	Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
6	[Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
7	The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.
8	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
9	Clinical pipeline report, company report or official report of Genentech (2009).